Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
11:37am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Analysts Expect AxoGen, Inc (NASDAQ:AXGN) Will Announce Quarterly Sales of $27.05 Million
06:28am, Thursday, 12'th Mar 2020
Analysts expect AxoGen, Inc (NASDAQ:AXGN) to post sales of $27.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AxoGen’s ea
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Stocks That Hit 52-Week Lows On Wednesday
03:41pm, Wednesday, 11'th Mar 2020
During Wednesday's morning session, 690 stocks hit new 52-week lows.
Intriguing Points:
Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new...
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
12:03pm, Wednesday, 11'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu
Bank of Montreal Can Has $3.04 Million Position in AxoGen, Inc (NASDAQ:AXGN)
08:38am, Monday, 09'th Mar 2020
Bank of Montreal Can boosted its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 154.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and E
AxoGen (NASDAQ:AXGN) Raised to "Strong-Buy" at ValuEngine
10:50am, Saturday, 07'th Mar 2020
ValuEngine upgraded shares of AxoGen (NASDAQ:AXGN) from a buy rating to a strong-buy rating in a report released on Tuesday, ValuEngine reports. A number of other equities research analysts have also
Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT
12:05pm, Friday, 06'th Mar 2020
Q4 2019 AxoGen Inc Earnings Call
Visiongain Launches Report Examining the Potential in the $118bn Translational Regenerative Medicine Market
10:00am, Friday, 06'th Mar 2020
The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in t
Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT
07:48pm, Wednesday, 04'th Mar 2020
Q4 2019 AxoGen Inc Earnings Call
Axogen, Inc. to Participate at Upcoming Investor Conferences
12:00pm, Monday, 02'nd Mar 2020
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team wil
Axogen, Inc. to Participate at Upcoming Investor Conferences
12:00pm, Monday, 02'nd Mar 2020
ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
AxoGen, Inc (NASDAQ:AXGN) Sees Large Decline in Short Interest
09:44am, Monday, 02'nd Mar 2020
AxoGen, Inc (NASDAQ:AXGN) saw a large drop in short interest in February. As of February 14th, there was short interest totalling 1,500,000 shares, a drop of 9.6% from the January 30th total of 1,660,
AxoGen, Inc (NASDAQ:AXGN) Expected to Earn FY2020 Earnings of ($0.69) Per Share
08:56am, Monday, 02'nd Mar 2020
AxoGen, Inc (NASDAQ:AXGN) – Cantor Fitzgerald decreased their FY2020 earnings per share (EPS) estimates for shares of AxoGen in a research note issued to investors on Wednesday, February 26th. Canto
